Labcorp Holdings Non-GAAP EPS of $4.78 beats by $0.14, revenue of $3.81B beats by $50M, rais

Labcorp Holdings reported Q3 Non-GAAP EPS of $4.78, exceeding estimates by $0.14. Revenue was $3.81B, up 7.0% Y/Y and $50M above expectations. The company raised full-year revenue growth guidance to 5.9% to 6.7% and adjusted EPS guidance.

Original reporting
Published Oct 28, 2026, 10:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LH
Bullish
high confidence
Mentioned
$LH
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$LHBullishMed
01

Why it matters

The earnings beat and raised guidance may attract new buying interest and support higher valuation multiples.

02

Market read

First report of Q3 earnings and guidance for Labcorp, a large‑cap healthcare firm, offering a clear trading catalyst.

03

What to watch

Potential headwinds from reimbursement policy changes could temper upside.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Labcorp is a leading global life sciences company providing diagnostic testing and drug development services.

Company-level read

Ticker impact

$LHBullishHigh confidence
Context

Labcorp reported Q3 Non-GAAP EPS of $4.78 beating expectations by $0.14 and raised full-year revenue growth guidance.

Expected impact

likely upward pressure as investors price in the beat and higher guidance

Evidence & confidence

Both earnings and guidance are fresh primary disclosures for a large‑cap company.

Market effects

Strong results may lift the broader healthcare services sector.

Positive for U.S. biotech and diagnostics stocks.

Reinforces confidence in U.S. earnings season, supporting global risk appetite.

Counterpoint

If the beat is already priced in, the stock could face short‑term profit taking.

Key entities

  • Labcorp Holdings

    Provider of clinical laboratory services and drug development.

Related articles

$LHHighAI 9/10

Labcorp completes $375M Millennium Health takeover

Labcorp completed its $375M acquisition of Millennium Health, including $245M upfront and up to $130M in milestone payments. The deal aims to enhance Labcorp's toxicology services and expand its geographic reach. Millennium specializes in drug testing, complementing Labcorp's existing offerings. Labcorp CEO Adam Schechter highlighted the strategic fit and growth potential during an earnings call.

$LHMed

Labcorp Finalizes Acquisition of Millennium Health to Expand Toxicology Testing

Labcorp has completed its acquisition of Millennium Health, a specialty lab focused on drug testing and surveillance. The deal aims to expand Labcorp's toxicology testing capabilities nationwide, providing insights for treating chronic pain, substance use disorders, and mental health conditions. Labcorp expects to integrate Millennium's expertise with its own network and digital solutions to improve patient care.

$OPKMed

OPKO Health Inc (OPK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 16% as LabCorp

OPKO Health Inc (OPK) reported Q3 2026 revenue growth of 16% YoY, driven by product revenue and strong performance from key products. The company expects to receive $722M in cash from the LabCorp transaction, plus up to $150M in royalties. OPK strengthened its balance sheet with $125M in financing and ended the quarter with $403.2M in cash. The company repurchased 7.2M shares for $10.6M.